ArticleImmunology2015
Immunology of naturally transmissible tumours.
Article in Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 50 citations in OpenAlex.
- Differences in Histopathology and Local Immune Response in Steady and Progressive Natural Transmissible Venereal Tumors in Mexican Dogs.Animals : an open access journal from MDPI · 2026Article
- Harmonized nonhuman cancer database.bioRxiv : the preprint server for biology · 2025Article
- Gene expression in soft-shell clam (Mya arenaria) transmissible cancer reveals survival mechanisms during host infection and seawater transfer.PLoS genetics · 2025Article
- Bridging clinic and wildlife care with AI-powered pan-species computational pathology.Nature communications · 2023Article
- PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.NPJ precision oncology · 2021Article
- Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer.Frontiers in oncology · 2021Review
- The evolution of resistance and tolerance as cancer defences.Parasitology · 2020Article
- Somatic evolution and global expansion of an ancient transmissible cancer lineage.Science (New York, N.Y.) · 2019Article
- Transmissible Cancers and Immune Downregulation in Tasmanian Devil (Comparative medicine · 2019Article
- Evaluation of a Canine Transmissible Venereal Tumour Cell Line with Tumour Immunity Capacity but Without Tumorigenic Property.Journal of veterinary research · 2019Article
- Article
- Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour.Veterinary medicine and science · 2018Article
- Cancer in wildlife: patterns of emergence.Nature reviews. Cancer · 2018Review
- The role of MHC genes in contagious cancer: the story of Tasmanian devils.Immunogenetics · 2017Review
- ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).PloS one · 2017Article
- A Sixth Modality of Infectious Disease: Contagious Cancer from Devils to Clams and Beyond.PLoS pathogens · 2016Review
- Cancer in the parasitic protozoans Trypanosoma brucei and Toxoplasma gondii.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Naturally transmissible tumours can emerge when a tumour cell gains the ability to pass as an infectious allograft between individuals. The ability of these tumours to colonize a new host and to cross histocompatibility barriers contradicts our understanding of the vertebrate immune response to allografts. Two naturally occurring contagious cancers are currently active in the animal kingdom, canine transmissible venereal tumour (CTVT), which spreads among dogs, and devil facial tumour disease (DFTD), among Tasmanian devils. CTVT are generally not fatal as a tumour-specific host immune response controls or clears the tumours after transmission and a period of growth. In contrast, the growth of DFTD tumours is not controlled by the Tasmanian devil's immune system and the disease causes close to 100% mortality, severely impacting the devil population. To avoid the immune response of the host both DFTD and CTVT use a variety of immune escape strategies that have similarities to many single organism tumours, including MHC loss and the expression of immunosuppressive cytokines. However, both tumours appear to have a complex interaction with the immune system of their respective host, which has evolved over the relatively long life of these tumours. The Tasmanian devil is struggling to survive with the burden of this disease and it is only with an understanding of how DFTD passes between individuals that a vaccine might be developed. Further, an understanding of how these tumours achieve natural transmissibility should provide insights into general mechanisms of immune escape that emerge during tumour evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.